Literature DB >> 28486459

Genentech's Ocrevus heralds new chapter in MS treatment.

Cormac Sheridan.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28486459     DOI： 10.1038/nbt0517-393

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

1.  Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.

Authors:  Rui Li; Ayman Rezk; Mathab Ghadiri; Felix Luessi; Frauke Zipp; Hulun Li; Paul S Giacomini; Jack Antel; Amit Bar-Or
Journal:  J Immunol       Date:  2016-12-14       Impact factor: 5.422

2.  Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Authors:  Stephen L Hauser; Amit Bar-Or; Giancarlo Comi; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Xavier Montalban; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Jerry S Wolinsky; Douglas L Arnold; Gaelle Klingelschmitt; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Peter Chin; Nicole Mairon; Hideki Garren; Ludwig Kappos
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

3.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Authors:  Xavier Montalban; Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Jérôme de Seze; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Annette Sauter; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Hideki Garren; Nicole Mairon; Peter Chin; Jerry S Wolinsky
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

Review 4.  The Charcot Lecture | beating MS: a story of B cells, with twists and turns.

Authors:  Stephen L Hauser
Journal:  Mult Scler       Date:  2014-12-05       Impact factor: 6.312

5.  Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.

Authors:  Jonatan Salzer; Rasmus Svenningsson; Peter Alping; Lenka Novakova; Anna Björck; Katharina Fink; Protik Islam-Jakobsson; Clas Malmeström; Markus Axelsson; Mattias Vågberg; Peter Sundström; Jan Lycke; Fredrik Piehl; Anders Svenningsson
Journal:  Neurology       Date:  2016-10-19       Impact factor: 9.910
  5 in total
  1 in total

1.  The Efficacy and Safety of Anti-CD20 Antibody Treatments in Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-analysis.

Authors:  Xin Wu; Xin Tan; Jie Zhang; Zilan Wang; Wenxue Wu; Shixin Wang; Yanfei Liu; Zhong Wang
Journal:  CNS Drugs       Date:  2022-10-16       Impact factor: 6.497
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.